Valuation: Aligos Therapeutics, Inc.

Market Cap 3.78Cr 3.3Cr 3.05Cr 2.8Cr 5.31Cr 363.52Cr 5.4Cr 36Cr 14Cr 177.68Cr 14Cr 14Cr 612.41Cr P/E 2026 *
-0.87x
P/E 2027 * -1.43x
Enterprise Value 1.45Cr 1.27Cr 1.17Cr 1.07Cr 2.04Cr 139.48Cr 2.07Cr 14Cr 5.48Cr 68Cr 5.44Cr 5.32Cr 234.98Cr EV / Sales 2026 *
0.67x
EV / Sales 2027 * -48.9x
Free-Float
77.71%
Yield 2026 *
-
Yield 2027 * -
1 day-4.83%
1 week-13.22%
Current month+1.21%
1 month+14.29%
3 months-21.29%
6 months-29.30%
Current year-37.34%
1 week 5.77
Extreme 5.77
7.08
1 month 4.98
Extreme 4.98
7.08
Current year 4.8
Extreme 4.8
10.49
1 year 4.8
Extreme 4.8
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

5,860 0.1088%
25/06Free

Director

5,860 0.1088%
25/06Free

Director

5,860 0.1088%
Change 5-day change 1-year change 3-year change Capi.($)
-4.83%-13.22%-31.29%-77.96% 3.78Cr
-0.17%+1.47%+3.16%+7.43% 5.04TCr
-0.21%-2.68%+388.43%+594.01% 3.93TCr
+0.34%+2.19%+32.08%-5.92% 3.47TCr
+1.53%+2.77%+15.03%+56.77% 3.41TCr
+1.68%-1.40%+4.23%+27.34% 2.66TCr
+0.25%-4.21% - - 1.65TCr
-0.38%+0.35%+70.72%+115.82% 1.53TCr
+0.43%+3.34%+14.96%+17.98% 1.38TCr
+0.80%+2.13%+16.09%-31.03% 1.29TCr
Average -0.05%-0.34%+57.04%+78.27% 2.44TCr
Weighted average by Cap. +0.42%-0.32%+82.20%+122.46%

Financials

2026 *2027 *
Net sales 2.17Cr 1.9Cr 1.75Cr 1.61Cr 3.05Cr 208.58Cr 3.1Cr 21Cr 8.19Cr 101.95Cr 8.14Cr 7.96Cr 351.38Cr 50L 43.72L 40.33L 37.07L 70.24L 48Cr 71.44L 4.81Cr 1.89Cr 24Cr 1.88Cr 1.84Cr 81Cr
Net income -9.39Cr -8.21Cr -7.57Cr -6.96Cr -13Cr -903.08Cr -13Cr -90Cr -35Cr -441.4Cr -35Cr -34Cr -1.52TCr -12Cr -11Cr -10Cr -9.21Cr -17Cr -1.2TCr -18Cr -119.6Cr -47Cr -584.18Cr -47Cr -46Cr -2.01TCr
Net Debt -2.33Cr -2.04Cr -1.88Cr -1.73Cr -3.27Cr -224.03Cr -3.33Cr -22Cr -8.8Cr -109.5Cr -8.74Cr -8.55Cr -377.43Cr -28Cr -25Cr -23Cr -21Cr -40Cr -2.72TCr -40Cr -271.69Cr -106.6Cr -1.33TCr -105.96Cr -103.64Cr -4.57TCr
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
15/26/15 $5.840 -4.34% 38,064
14/26/14 $6.105 -4.01% 1,02,514
13/26/13 $6.360 -3.93% 1,89,230
10/26/10 $6.620 -2.22% 1,09,531
09/26/09 $6.770 +0.59% 1,95,735
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.105USD
Average target price
56.29USD
Spread / Average Target
+821.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock